Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

5.4K
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
5.4K
Tumor Progression02:07

Tumor Progression

6.5K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinicopathological, Molecular and DNA Methylation Analysis of Ossifying Fibromyxoid Tumors Delineates the ZC3H7B::BCOR Subset as a Distinct Entity.

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc·2026
Same author

A Spatial Atlas of Muscle-Invasive Bladder Cancer Reveals Lineage-Specific Vulnerabilities and Immune Architecture.

Cancer discovery·2026
Same author

Pitfalls in diagnosis of metatypical adenoid cystic carcinoma.

Histopathology·2026
Same author

Tumoural emboli syndromes case series: diagnostic dilemma in patients with cancer and pulmonary hypertension.

European heart journal. Case reports·2026
Same author

Case Report: Complete response to the concurrent neoadjuvant radiation therapy and pembrolizumab in a locally recurrent, chemotherapy-refractory undifferentiated pleomorphic sarcoma of bone.

Frontiers in oncology·2026
Same author

Ossifying spindled and epithelioid tumour: Expanding the clinical and morphologic spectrum of a recently described entity.

Histopathology·2026
Same journal

Update on the molecular pathology of the distinctive giant cell, fibro-osseous and bone forming lesions of the jaws.

Seminars in diagnostic pathology·2026
Same journal

Update on the molecular pathology and classification of odontogenic cysts and tumours.

Seminars in diagnostic pathology·2026
Same journal

MDM2 gene amplification in surgical pathology: biology, diagnostic utility, and clinical relevance in the modern era.

Seminars in diagnostic pathology·2026
Same journal

When three negatives equal a positive: Molecular updates of triple-negative breast carcinomas with favorable prognoses.

Seminars in diagnostic pathology·2026
Same journal

Old school, new insight: Revisiting histomorphology in the modern era of prostate cancer risk stratification.

Seminars in diagnostic pathology·2026
Same journal

Recent advances in genetic predisposition to primary testicular tumors.

Seminars in diagnostic pathology·2026
See all related articles

Related Experiment Video

Updated: Sep 17, 2025

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies
07:15

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies

Published on: July 28, 2020

9.7K

NUT-rearranged sarcoma.

Sintawat Wangsiricharoen1, Jeanne M Meis2, Wendong Yu2

  • 1Department of Pathology and Laboratory Medicine, Oregon Health & Science University, Portland, OR 97239, USA.

Seminars in Diagnostic Pathology
|July 3, 2025
PubMed
Summary
This summary is machine-generated.

NUT-rearranged sarcoma is a distinct soft tissue cancer defined by NUT gene rearrangement. It differs from NUT carcinoma and may not respond to BET inhibitor treatments.

Keywords:
MGAMXD1MXD4MXI1NUTM1NUTM2Sarcoma

More Related Videos

Author Spotlight: Genetically Engineered Mouse Models and Pathological Characterization of Neurofibromatosis Type 1 Associated Tumors
08:57

Author Spotlight: Genetically Engineered Mouse Models and Pathological Characterization of Neurofibromatosis Type 1 Associated Tumors

Published on: May 17, 2024

2.1K
A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate
07:31

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate

Published on: May 3, 2021

3.8K

Related Experiment Videos

Last Updated: Sep 17, 2025

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies
07:15

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies

Published on: July 28, 2020

9.7K
Author Spotlight: Genetically Engineered Mouse Models and Pathological Characterization of Neurofibromatosis Type 1 Associated Tumors
08:57

Author Spotlight: Genetically Engineered Mouse Models and Pathological Characterization of Neurofibromatosis Type 1 Associated Tumors

Published on: May 17, 2024

2.1K
A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate
07:31

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate

Published on: May 3, 2021

3.8K

Area of Science:

  • Oncology
  • Pathology
  • Genetics

Background:

  • NUT-rearranged sarcoma is an emerging entity within soft tissue sarcomas.
  • It is characterized by specific NUT gene rearrangements and is distinct from NUT carcinoma.
  • These tumors exhibit diverse histological patterns and affect various body sites and age groups.

Purpose of the Study:

  • To define the distinct clinicopathologic features of NUT-rearranged sarcoma.
  • To differentiate NUT-rearranged sarcoma from NUT carcinoma.
  • To explore potential therapeutic implications based on molecular characteristics.

Main Methods:

  • Histopathological analysis of tumor samples.
  • Immunohistochemical staining for NUT and other markers.
  • Molecular genetic analysis to identify gene rearrangements, particularly involving the MAD transcription family.

Main Results:

  • NUT-rearranged sarcomas present with varied growth patterns (fibrosarcomatous, round cell, epithelioid/rhabdoid, hyalinized/nested).
  • Tumor cells typically express NUT, with exceptions in NUTM2-rearranged cases.
  • Molecular analysis frequently implicates genes in the MAD transcription family.

Conclusions:

  • NUT-rearranged sarcoma represents a unique sarcoma subtype with distinct histological and molecular features.
  • It differs significantly from NUT carcinoma.
  • The efficacy of BET inhibitors, effective in NUT carcinoma, may be limited in NUT-rearranged sarcoma, suggesting different therapeutic strategies.